Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same
AssigneeThomas Jefferson University
InventorsScott A. Waldman, Adam E. Snook, Michael S. Magee
Life of this patent
Estimating the term…
Loading patent…
AssigneeThomas Jefferson University
InventorsScott A. Waldman, Adam E. Snook, Michael S. Magee
Estimating the term…
Isolated pluralities of T cells which recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and T cells comprising such nucleic acid molecules.
A plurality of T cells which recognize at least one epitope of guanylyl cyclase C and which are modified to inhibit expression or activity of α4β7 integrin and chemokine receptor 9 (CCR9);
Dependencies are inferred from the claim text.